-
Nov 10, 2020Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021
-
Nov 2, 2020- Credit Suisse - 29th Annual Healthcare Conference - November 9th -12th
-
Sep 10, 2020- Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration